Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-049511
Filing Date
2025-05-15
Accepted
2025-05-15 16:33:01
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9520
  Complete submission text file 0001104659-25-049511.txt   11517
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Subject) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-79996 | Film No.: 25954247
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840 203-404-1172
Nantahala Capital Management, LLC (Filed by) CIK: 0001472322 (see all company filings)

EIN.: 201151760 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G